article thumbnail

IN FOCUS: Syngene International

Pharmaceutical Technology

Its scope includes Syngene providing integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. until 2026. Syngene’s collaboration with Zoetis started in 2011.

article thumbnail

Overcoming inefficiencies to improve access to cell and gene therapy 

Drug Discovery World

Repercussions of the Covid-19 pandemic The idea that the Covid-19 pandemic dramatically affected the CGT supply chain and upturned CGT manufacturing has dominated the conversation in the biotech sector 3. But now, the increased efficiency is likely making drug development cheaper. So what bottlenecks are making CGT so inaccessible?